Literature DB >> 32447196

MmpL3 inhibitors as antituberculosis drugs.

Min Shao1, Matthew McNeil2, Gregory M Cook2, Xiaoyun Lu3.   

Abstract

The mycobacterial membrane protein Large 3 (MmpL3) is an inner membrane protein that transports trehalose-monomycolates, precursors for trehalose-dimycolates and mycolic acids that make up essential components of the mycobacterial outer membrane. Inhibition of MmpL3 weakens the mycobacterial cell wall and ultimately results in cell death in both in vitro and in vivo infection models. This highlights the therapeutic potential of MmpL3 as a drug target. High-throughput whole-cell screening along with whole genome sequencing of resistant mutants has identified numerous classes of compounds that can be classified as MmpL3 inhibitors. In this review, we provide insights into the current development of various MmpL3 inhibitors and discuss the potential challenges in this area.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antituberculosis drug; Drug design; MmpL3 inhibitor; SAR

Year:  2020        PMID: 32447196     DOI: 10.1016/j.ejmech.2020.112390

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

1.  Computational design of MmpL3 inhibitors for tuberculosis therapy.

Authors:  R Chaitra; Rohit Gandhi; N Jayanna; Sachin Satyanath; Parasuraman Pavadai; Manikanta Murahari
Journal:  Mol Divers       Date:  2022-04-28       Impact factor: 2.943

2.  Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis.

Authors:  Hongyi Zhao; Yongxin Gao; Wei Li; Li Sheng; Keli Cui; Bin Wang; Lei Fu; Meng Gao; Ziyun Lin; Xiaowen Zou; Mary Jackson; Haihong Huang; Yu Lu; Dongfeng Zhang
Journal:  J Med Chem       Date:  2022-08-01       Impact factor: 8.039

3.  The driving force for mycolic acid export by mycobacterial MmpL3 is proton translocation.

Authors:  Tanya Parish
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-08       Impact factor: 12.779

Review 4.  Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.

Authors:  Tafere Mulaw Belete
Journal:  Microbiol Insights       Date:  2022-05-23

Review 5.  Structural and Functional Diversity of Resistance-Nodulation-Cell Division Transporters.

Authors:  Philip A Klenotic; Mitchell A Moseng; Christopher E Morgan; Edward W Yu
Journal:  Chem Rev       Date:  2020-11-19       Impact factor: 60.622

Review 6.  Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis.

Authors:  Wenbin Kuang; Haolin Zhang; Xiao Wang; Peng Yang
Journal:  Acta Pharm Sin B       Date:  2022-04-27       Impact factor: 14.903

7.  Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening.

Authors:  Anuradha Kumar; Somsundaram Chettiar; Brian S Brown; Julie Early; Juliane Ollinger; Megan Files; Mai A Bailey; Aaron Korkegian; Devon Dennison; Matthew McNeil; James Metz; Augustine Osuma; Michael Curtin; Aaron Kunzer; Gail Freiberg; Milan Bruncko; Dale Kempf; Tanya Parish
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

Review 8.  Physicochemical properties and Mycobacterium tuberculosis transporters: keys to efficacious antitubercular drugs?

Authors:  Elizabeth Fullam; Robert J Young
Journal:  RSC Med Chem       Date:  2020-12-07

9.  Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: An emergent therapeutic target.

Authors:  Oliver Adams; Justin C Deme; Joanne L Parker; Philip W Fowler; Susan M Lea; Simon Newstead
Journal:  Structure       Date:  2021-07-08       Impact factor: 5.006

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.